LON:HCM - HUTCHMED Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 374
▼ -22 (-5.56%)

This chart shows the closing price for HCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New HUTCHMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCM

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for HUTCHMED in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 374.

This chart shows the closing price for HCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in HUTCHMED. This rating has held steady since February 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/15/2020BarclaysReiterated RatingEqual weight
12/11/2019Morgan StanleyInitiated CoverageEqual weightGBX 360
3/27/2019HSBCInitiated CoverageBuyGBX 5,940
2/14/2018Beaufort SecuritiesReiterated RatingBuy
8/29/2017Panmure GordonReiterated RatingBuyGBX 3,840
8/1/2017Beaufort SecuritiesReiterated RatingBuy
6/30/2017Beaufort SecuritiesReiterated RatingBuy
6/22/2017Panmure GordonReiterated RatingBuyGBX 3,530
6/13/2017Beaufort SecuritiesReiterated RatingBuy
5/18/2017Panmure GordonBoost Price TargetBuyGBX 2,900 ➝ GBX 3,530
3/14/2017Beaufort SecuritiesReiterated RatingBuy
3/6/2017Beaufort SecuritiesReiterated RatingBuy
2/20/2017Panmure GordonReiterated RatingBuyGBX 2,630
2/15/2017Beaufort SecuritiesReiterated RatingBuy
2/1/2017Panmure GordonReiterated RatingBuyGBX 2,630
1/26/2017Panmure GordonReiterated RatingBuyGBX 2,630
1/11/2017Panmure GordonReiterated RatingBuyGBX 2,630
1/5/2017Panmure GordonReiterated RatingBuyGBX 2,630
12/5/2016Panmure GordonReiterated RatingBuyGBX 2,630
11/23/2016Panmure GordonReiterated RatingBuyGBX 2,630
11/1/2016Beaufort SecuritiesReiterated RatingBuy
10/31/2016Panmure GordonReiterated RatingBuyGBX 2,630
9/16/2016Panmure GordonReiterated RatingBuyGBX 2,630
8/3/2016Beaufort SecuritiesReiterated RatingBuy
8/1/2016Panmure GordonReiterated RatingUnder Review
(Data available from 6/22/2016 forward)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. HUTCHMED (China) Limited has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Read More

Today's Range

Now: GBX 374
Low: 370.84
High: 390.49

50 Day Range

MA: GBX 402.32
Low: 352
High: 438

52 Week Range

Now: GBX 374
Low: 337
High: 538


77,046 shs

Average Volume

67,081 shs

Market Capitalization

£2.78 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of HUTCHMED?

The following sell-side analysts have issued stock ratings on HUTCHMED in the last year: Barclays PLC.
View the latest analyst ratings for HCM.

What is the current price target for HUTCHMED?

0 Wall Street analysts have set twelve-month price targets for HUTCHMED in the last year. has the lowest price target set, forecasting a price of £100,000 for HUTCHMED in the next year.
View the latest price targets for HCM.

What is the current consensus analyst rating for HUTCHMED?

HUTCHMED currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HCM, but not buy more shares or sell existing shares.
View the latest ratings for HCM.

What other companies compete with HUTCHMED?

How do I contact HUTCHMED's investor relations team?

The company's listed phone number is +85221213888. The official website for HUTCHMED is www.chi-med.com.